Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational I...(President of U.S. MedicalAffairs at Acte...)

About PAH Pathways and Sure Steps

PAH Pathways(TM) is Actelion's service and support program for physicians and their patients currently on either of Actelion's PAH medications, including Tracleer and Ventavis. The program is designed to provide access to therapy, ensuring patients receive therapy as quickly as possible, and comprehensive financial and reimbursement support to eligible patients. In addition, PAH Pathways recently introduced a program that offers eligible patients starting on Tracleer with their first month of therapy at no cost to the patient.

Sure Steps, an important part of the PAH Pathways offering, is a support and education program for patients with PAH who are taking one of Actelion's PAH medications. The program provides ongoing information and personal assistance to help these patients manage their condition. Patients enrolled in Sure Steps receive direct access to a nurse counselor who can help answer questions regarding PAH or Tracleer, ongoing informational newsletters, and important tools to help them cope with PAH. Over 3,500 patients have enrolled in Sure Steps to date. Eligible patients can enroll by calling 1-866-682-7873. Sure Steps is also available to patients who are taking Ventavis for the treatment PAH.

About Tracleer(R) in Pulmonary Arterial Hypertension (PAH)

Tracleer(R) (bosentan), the first oral dual endothelin receptor antagonist, is approved for the treatment of pulmonary arterial hypertension (PAH) World Health Organization (WHO) Functional Class III or IV and made available by Actelion Ltd. subsidiaries in the United States, the European Union, Japan, Australia, Canada, Switzerland and other markets worldwide.

Tracleer requires attention to t
'/>"/>